BofA Securities Reiterates Buy Rating on Vera Therapeutics (VERA): Vertex data "appears to pose no real threat"

March 9, 2026 5:40 PM

BofA Securities analyst Dina Ramadane reiterated a Buy rating and $66.00 price target on Vera Therapeutics (NASDAQ: VERA)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found